Paper Details

  1. Home
  2. Paper Details

Safety considerations when treating myelofibrosis.

Author: HarrisonC N, McLornanD P, O'SullivanJ M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Ruxolitinib is an effective treatment option for patients with myelofibrosis, but careful consideration should be given to managing patients who lose their response to JAK inhibitor therapies.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Myelofibrosis (MF) is a clonal disorder leading to marrow fibrosis, cytopenias and extramedullary haematopoiesis. AREAS COVERED: Generic management of MF with a specific focus on the efficacy and safety profile of the Janus Kinase (JAK)1/JAK 2 kinase inhibitor, ruxolitinib (Novartis P...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14740338.2016.1185414

データ提供：米国国立医学図書館（NLM）

Myelofibrosis: A Complex Disease with New Treatment Options

The treatment of myelofibrosis (MF), a complex blood disorder, is constantly evolving. This study examines the efficacy and safety of ruxolitinib, a novel JAK inhibitor for MF, as well as other therapeutic options.

Navigating the Desert of Myelofibrosis Treatment

The study discusses the challenges of managing MF, highlighting the potential benefits and risks associated with various treatments. The researchers explore the efficacy and safety profile of ruxolitinib, a JAK inhibitor that has emerged as a promising treatment option.

Navigating the Desert of Myelofibrosis Treatment

The study concludes that ruxolitinib offers significant benefits for many patients with symptomatic MF, offering a glimmer of hope in the desert of MF treatment. However, the authors also caution about potential side effects and the need for careful management of patients who lose their response to treatment.

Dr. Camel's Conclusion

This study provides a comprehensive overview of current treatment options for myelofibrosis. Ruxolitinib represents a significant advance in the management of this complex disease, but careful monitoring and personalized treatment strategies are essential for achieving optimal outcomes.

Date :
  1. Date Completed 2017-02-27
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

27187785

DOI: Digital Object Identifier

10.1080/14740338.2016.1185414

Related Literature

Article Analysis
・Side Effects of momelotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.